Resonance Health

Resonance Health Revenue

The The revenue of Resonance Health (RHT.AX) as of Oct 27, 2026 is 15.75 M AUD. In the previous year, The revenue was 11.07 M AUD — a change of 42.25% (higher).

Revenue

15.75 MAUD

YoY

42.25%

Last updated:

In 2026, Resonance Health's sales reached 15.75 M AUD, a 42.25% difference from the 11.07 M AUD sales recorded in the previous year.

Revenue has compounded at 11.9% per year over the past 19 years to 15.75 M AUD.

The Resonance Health Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2020
3.67 M AUD
Jan 1, 2021
3.78 M AUD
Jan 1, 2022
3.83 M AUD
Jan 1, 2023
4.40 M AUD
Jan 1, 2024
8.59 M AUD
Jan 1, 2025
11.07 M AUD
Jan 1, 2026
15.75 M AUD
Jan 1, 2027 (e)
0.00 AUD
The Resonance Health Revenue history
YEARRevenueYoY
est0.00AUD-100.00%
15.75 MAUD+42.25%
11.07 MAUD+28.92%
8.59 MAUD+95.03%
4.40 MAUD+15.05%
3.83 MAUD+1.30%
3.78 MAUD+3.03%
3.67 MAUD+1.19%
3.63 MAUD+25.17%
2.90 MAUD+16.54%
2.49 MAUD-2.47%
2.55 MAUD+4.30%
2.44 MAUD+6.91%
2.29 MAUD+49.64%
1.53 MAUD-2.24%
1.56 MAUD-10.54%
1.75 MAUD-5.01%
1.84 MAUD-18.64%
2.26 MAUD+31.18%
1.72 MAUD-7.87%
1.87 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resonance Health Revenue

Resonance Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.67 M AUD
-1.18 M AUD
-715,000.00 AUD
Jan 1, 2021
3.78 M AUD
188,190.00 AUD
585,858.00 AUD
Jan 1, 2022
3.83 M AUD
-1.77 M AUD
-1.14 M AUD
Jan 1, 2023
4.40 M AUD
-1.62 M AUD
-780,000.00 AUD
Jan 1, 2024
8.59 M AUD
-879,000.00 AUD
169,303.00 AUD
Jan 1, 2025
11.07 M AUD
-1.93 M AUD
-1.73 M AUD
Jan 1, 2026
15.75 M AUD
1.53 M AUD
1.51 M AUD
Jan 1, 2027 (e)
0.00 AUD
0.00 AUD
0.00 AUD

Resonance Health Margins

Resonance Health stock margins

The Resonance Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resonance Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resonance Health.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-32.17 %
-19.49 %
Jan 1, 2021
100.00 %
4.98 %
15.50 %
Jan 1, 2022
100.00 %
-46.29 %
-29.83 %
Jan 1, 2023
100.00 %
-36.89 %
-17.71 %
Jan 1, 2024
100.00 %
-10.23 %
1.97 %
Jan 1, 2025
100.00 %
-17.42 %
-15.65 %
Jan 1, 2026
93.95 %
9.72 %
9.61 %
Jan 1, 2027 (e)
93.95 %
0.00 %
0.00 %

Resonance Health Stock analysis

What does Resonance Health do? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Resonance Health's Sales Figures

The sales figures of Resonance Health originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Resonance Health’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Resonance Health's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Resonance Health’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Resonance Health stock

The revenue of Resonance Health is 15.75 M AUD in 2026.

The revenue of Resonance Health changed from 11.07 M AUD to 15.75 M AUD, representing a 42.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Resonance Health since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Resonance Health historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Resonance Health

All Key Metrics — Resonance Health